

# Resource Summary Report

Generated by [ASWG](#) on Aug 14, 2026

## Phospho-FAK (Tyr397) (D20B1) Rabbit mAb

RRID:AB\_10891442

Type: Antibody

---

### Proper Citation

Cell Signaling Technology Cat# 8556, RRID:AB\_10891442

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_10891442](http://antibodyregistry.org/AB_10891442)

**Proper Citation:** Cell Signaling Technology Cat# 8556, RRID:AB\_10891442

**Target Antigen:** Phospho-FAK (Tyr397) (D20B1) Rabbit mAb

**Host Organism:** rabbit

**Clonality:** monoclonal

**Comments:** Applications: W, IP

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

**Antibody Name:** Phospho-FAK (Tyr397) (D20B1) Rabbit mAb

**Description:** This monoclonal targets Phospho-FAK (Tyr397) (D20B1) Rabbit mAb

**Target Organism:** rat, h, m, mouse, r, human, mk

**Antibody ID:** AB\_10891442

**Vendor:** Cell Signaling Technology

**Catalog Number:** 8556

**Record Creation Time:** 20250819T233844+0000

**Record Last Update:** 20250820T055830+0000

---

### Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for Phospho-FAK (Tyr397) (D20B1) Rabbit mAb.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 68 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [ASWG](#) .

Peng H, et al. (2026) Eukaryote initiation factor 6 modulates small-cell lung carcinoma plasticity via the integrin-FAK signaling axis. Nature communications, 17(1).

Govindarajan M, et al. (2026) Pan-cancer N-glycoproteomic atlas of patient-derived xenografts uncovers FAT2 as an actionable surface target. Cell reports. Medicine, 7(2), 102578.

Papaioannou G, et al. (2026) Regulation of cAMP levels in osteocytes by mechano-sensitive focal adhesion kinase and phosphodiesterase 8A. iScience, 29(6), 116049.

Nishinaka T, et al. (2026) IL-4/IL-13 signaling suppresses ABT-263-induced apoptosis in senescent human fibroblasts. International immunopharmacology, 184, 116939.

Lee SH, et al. (2025) Dynamic decoding of VEGF signaling and coordinated control of multiple phenotypes by the Src-TEM4-YAP pathway. Cell systems, 16(7), 101321.

Gu Y, et al. (2025) Clioquinol inhibits angiogenesis by promoting VEGFR2 degradation and synergizes with AKT inhibition to suppress triple-negative breast cancer vascularization. Angiogenesis, 28(2), 13.

Zhang S, et al. (2025) Vitamin D Binding Protein, a Ligand of Integrin beta 1, Motivates Both Tumor Cells and Schwann Cells to Promote Perineural Invasion in Pancreatic Ductal Adenocarcinoma. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e11726.

He D, et al. (2025) Chemotherapy awakens dormant cancer cells in lung by inducing neutrophil extracellular traps. Cancer cell, 43(9), 1622.

Sun Y, et al. (2025) CRB2 depletion induces YAP signaling and disrupts mechanosensing in podocytes. American journal of physiology. Renal physiology, 328(4), F578.

Liu B, et al. (2025) The hexosamine biosynthetic pathway drives tumor immune evasion via translational control of PD-L1 at the elongation level. *Cell reports*, 44(9), 116249.

Lubosch A, et al. (2025) The immune response against cancer is modulated by stromal cell fibronectin. *Neoplasia (New York, N.Y.)*, 67, 101196.

Lubrano S, et al. (2025) FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma. *Cancer cell*, 43(3), 428.

Matkar S, et al. (2025) Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma. *Molecular cancer therapeutics*, 24(9), 1389.

Kopietz F, et al. (2025) Focal Adhesion Kinase Orchestrates GLUT4 Translocation and Glucose Uptake via Cytoskeletal Turnover in Primary Adipocytes. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 39(10), e70660.

Pequerul R, et al. (2025) Inter- and intra-tumoral ALDH1 heterogeneity in breast cancer identifies therapeutic opportunities for ALDH1A-specific inhibitors. *Cell chemical biology*.

Xi C, et al. (2024) Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway. *iScience*, 27(6), 109829.

Zhao Y, et al. (2024) Mechanochemical coupling of MGF mediates periodontal regeneration. *Bioengineering & translational medicine*, 9(1), e10603.

Akhter MZ, et al. (2024) FAK regulates tension transmission to the nucleus and endothelial transcriptome independent of kinase activity. *Cell reports*, 43(6), 114297.

Northey JJ, et al. (2024) Mechanosensitive hormone signaling promotes mammary progenitor expansion and breast cancer risk. *Cell stem cell*, 31(1), 106.

Benwell CJ, et al. (2024) A proteomics approach to isolating neuropilin-dependent  $\alpha 5$  integrin trafficking pathways: neuropilin 1 and 2 co-traffic  $\alpha 5$  integrin through endosomal p120RasGAP to promote polarised fibronectin fibrillogenesis in endothelial cells. *Communications biology*, 7(1), 629.